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Introduction: This study evaluated various remission criteria in abatacept plus methotrexate (MTX)-treated patients
with early rheumatoid arthritis (RA). We aimed to investigate the time to, and sustainability of, remission, and to
evaluate the relationship between remission, function and structure.
Methods: Post hoc analyses were performed from the 12-month, double-blind period of the Abatacept study to
Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid
arthritis (AGREE) in patients with early RA (≤2 years) and poor prognostic factors, comparing abatacept plus MTX
(n = 210) versus MTX alone (n = 209).
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Results: At month 12, Disease Activity Score 28, Simplified Disease Activity Index (SDAI), Clinical Disease Activity
Index and Boolean remission rates were, for abatacept plus MTX versus MTX alone: 47.6 % versus 27.3 %, 33.3 %
versus 12.4 %, 34.3 % versus 16.3 %, and 23.8 % versus 5.7 %, respectively. Cumulative probability demonstrated
higher proportions achieving first remission and first sustained remission for abatacept plus MTX versus MTX alone
(e.g., 23.3 % [95 % confidence interval (CI): 17.6, 29.1] vs 12.9 % [8.4, 17.5] for first SDAI remission over 0–6 months).
For patients in SDAI remission at month 3, mean Health Assessment Questionnaire-Disability Index at month 12 was
0.20 versus 0.50 for abatacept plus MTX versus MTX alone. Mean changes in radiographic score from baseline to month
12 were minimal for patients in SDAI remission at month 3 in both groups, while less structural damage progression
was seen, 0.75 versus 1.35, respectively, for abatacept plus MTX versus MTX alone for patients with moderate/high
disease activity at month 3 (adjusted mean treatment difference: −0.60 [95 % CI: −1.11, −0.09; P < 0.05]).
Conclusions: High proportions of abatacept plus MTX-treated patients achieved stringent remission criteria.
Remission was associated with long-term functional benefit; dissociation was seen between clinical and structural
outcomes for abatacept. These findings highlight the impact of reaching stringent remission targets early, on
physical function and structural damage, in MTX-naïve biologic-treated patients.
Trial registration: ClinicalTrials.gov identifier NCT00122382. Registered 19 July 2005.Introduction
According to the treat-to-target principle, patients with
rheumatoid arthritis (RA) should be monitored closely,
with the goal of achieving clinical remission or low disease
activity (LDA) within 6 months [1, 2], and then regularly
assessed for sustained remission [3]. Various criteria have
been used to formally define remission in clinical trials, of
which the Disease Activity Score (DAS)28 (score of <2.6)
has traditionally been used most frequently. However,
patients in DAS28 remission may experience residual
disease activity, as evidenced by swollen joint count
(SJC) in particular [4–7], which can lead to irreversible
structural damage [8, 9]. American College of Rheuma-
tology (ACR)-European League Against Rheumatism
(EULAR) recommendations [2] advocate using more
stringent remission criteria, namely the Simplified Dis-
ease Activity Index (SDAI) and a Boolean definition.
Alternative definitions proposed for use in clinical
practice, where measurement of acute-phase reactants
is often unavailable, are the Clinical Disease Activity
Index (CDAI) and a corresponding Boolean definition.
Abatacept is a biologic disease-modifying antirheu-
matic drug (DMARD) that selectively modulates T cell
co-stimulation [10] and has shown efficacy in several
clinical trials, including the Abatacept study to Gauge
Remission and joint damage progression in methotrexate
(MTX)-naive patients with Early Erosive rheumatoid
arthritis (AGREE) [10–12].
The main objective of the present analysis was to ex-
plore remission in patients with early RA treated with
abatacept plus MTX in light of the current, stringent
ACR-EULAR definitions of remission [2]. These new re-
mission criteria are frequently believed to be difficult to
achieve [13, 14]. Therefore, we evaluated patients with
early RA who had been treated with either MTX aloneor abatacept plus MTX in the AGREE trial. We also in-
vestigated sustainability of initial remission and evalu-
ated the relationship of disease activity with function
and structure in these patients. As will be demonstrated,
a considerable number of patients can indeed achieve
(and sustain) remission, even when using the new and
stringent remission criteria.
Methods
Patient population and study design
This post hoc analysis is based on data from the previously
published AGREE Phase III study (ClinicalTrials.gov identi-
fier NCT00122382), in which patients were randomized
(1:1) to receive abatacept plus MTX or MTX alone over a
12-month, double-blind period [15]. Patients were MTX
naïve (or prior exposure was ≤10 mg/week for ≤3 months);
had early RA (≤2 years); were positive for rheumatoid factor
and/or anti-cyclic citrullinated peptide antibodies; had evi-
dence of erosive changes on hands, wrists or feet; and had
tender joint count (TJC) ≥12, SJC ≥10 and C-reactive pro-
tein (CRP) ≥4.5 mg/dL.
Outcome measures
Individual core set variables [16] were assessed monthly.
Although DAS28 (CRP) <2.6 (DAS28 remission) [17] at
month 12 was a co-primary endpoint of the original
study, in this post hoc analysis we calculated ACR-
EULAR index-based remission rates, with remission de-
fined as SDAI ≤3.3 and CDAI ≤2.8 (see Additional file 1:
Table S1) [2, 4, 18, 19]. Remission according to the
ACR-EULAR Boolean definitions (clinical practice with
28-joint counts: TJC28 ≤1, SJC28 ≤1 and patient global
assessment (PGA) ≤1; clinical trials with 28-joint counts
and laboratory measures: TJC28 ≤1, SJC28 ≤1, CRP ≤1
mg/dL and PGA ≤1; clinical practice with 66/68-joint
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als with 66/68-joint counts and laboratory measures:
TJC68 ≤1, SJC66 ≤1, PGA ≤1 and CRP ≤1 mg/dL) was
also evaluated post hoc [2]. Level of disease activity was
measured using DAS28 (CRP), SDAI and CDAI (low dis-
ease activity (LDA), SDAI >3.3–11, CDAI >2.8–10 or
DAS28 ≤3.2; moderate disease activity (MDA), SDAI >11–
26, CDAI >10–22, or DAS28 >3.2– ≤ 5.1; high disease ac-
tivity (HDA), SDAI >26, CDAI >22, or DAS28 >5.1).
Functional disability was evaluated monthly using the
Health Assessment Questionnaire-Disability Index (HAQ-
DI). Structural damage progression was evaluated by radio-
graphs at baseline and month 12, with changes over time
evaluated according to the total Genant-modified Sharp
score (TGSS) [20] and non-progression defined as a mean
change in TGSS of ≤0.
Statistical analyses
In the original study, DAS28 (CRP)-defined remission
was evaluated for the intention-to-treat population, with
patients who discontinued considered non-responders.
For the purpose of this report, analyses were based on
patients with DAS28 and SDAI data available at baseline,
month 6 and month 12. Analyses were performed post
hoc for patients who had received abatacept plus MTX
or MTX alone in the double-blind period. The propor-
tions of patients achieving remission and LDA according
to DAS28 (CRP), SDAI and CDAI, and remission according
to Boolean outcomes, were analyzed as point estimates with
95 % confidence intervals (CI). Analyses were performed to
determine shifts in SDAI status (remission, LDA, MDA
and HDA) from month 6 to 12, presented as the propor-
tions of patients in each SDAI state at month 6 who
achieved each SDAI state at month 12. Cumulative prob-
ability of time to achieve first remission/LDA and sustained
first remission/LDA (defined as maintained at all subse-
quent visits up to month 12) according to DAS28, SDAI
and CDAI were evaluated based on Kaplan–Meier estima-
tion with 95 % CI. Patients who lost first remission/LDA
status were censored at the time of loss.
The relationship between DAS28, SDAI and CDAI re-
mission was investigated by determining the proportions
(95 % CI) of patients in DAS28 remission who had also
achieved SDAI or CDAI remission, and by evaluation of
the median values of core set variables (TJC, SJC, PGA,
evaluator’s global assessment (EGA), CRP, erythrocyte
sedimentation rate (ESR)) for patients achieving remis-
sion. We also evaluated mean scores for core set vari-
ables for patients achieving remission at month 12 but
not at month 6. Finally, we evaluated the relationship
between disease activity at month 3 and functional and
structural outcomes at month 12, including mean scores
(SD) and mean changes (95 % CI) by disease activity sta-
tus (remission, LDA or MDA and HDA pooled) atmonths 3 and 12. Mean changes, treatment differences
and corresponding 95 % CI were adjusted based on an
analysis of covariance model with treatment, baseline
score and disease status as covariates.
Results
Patient disposition
In the original AGREE study, 253 and 256 patients were
randomized to receive MTX alone and abatacept plus
MTX, respectively; 227 and 232 patients, respectively,
completed the 12-month, double-blind period [15]. Dis-
continuations were mainly due to adverse events (4.3 %
in the MTX alone group vs 3.5 % in the abatacept plus
MTX group) and lack of efficacy (3.2 % and 0 %, respect-
ively). Included in this post hoc analysis were 209 pa-
tients receiving MTX alone and 210 receiving abatacept
plus MTX, with DAS28 and SDAI data available at base-
line, month 6 and month 12.
Baseline demographics and clinical characteristics
Demographics and baseline clinical characteristics for
the analysis population were comparable between groups
(see Additional file 2: Table S2), and were similar to
those reported previously for the overall study popula-
tion [15] with mean disease duration of ≤7 months and
high mean disease activity levels. In both treatment
groups, patients attaining remission or LDA at month
12 generally had numerically lower baseline TJC, SJC
and DAS28, SDAI and CDAI, as well as mean duration
of RA, than patients with MDA or HDA at month 12
(see Additional file 3: Table S3).
Remission outcomes
At month 12, remission was achieved in 27.3 % (95 % CI
21.2, 33.3) of patients receiving MTX alone compared
with 47.6 % (95 % CI 40.9, 54.4) of patients receiving
abatacept plus MTX by DAS28 criteria, by 12.4 % (95 %
CI 8.0, 16.9) and 33.3 % (95 % CI 27.0, 39.7) by SDAI
criteria, by 16.3 % (95 % CI 11.3, 21.3) and 34.3 % (95 %
CI 27.9, 40.7) by CDAI criteria, and by 5.7 % (95 % CI
2.6, 8.9) and 23.8 % (95 % CI 18.0, 29.6) by Boolean cri-
teria (the 95 % CI did not overlap) (Fig. 1). Thus, a large
proportion of patients achieved remission according to
the stringent SDAI, CDAI and Boolean criteria, al-
though, as expected, fewer than by DAS28 (CRP) cri-
teria. Indeed, one out of three patients achieved SDAI
remission and almost 25 % of patients achieved Boolean-
defined remission (28-joint count with laboratory mea-
sures) at month 12. Similar respective rates were seen
for CDAI remission and for Boolean remission evaluated
without CRP using 66/68-joint counts (see Additional
file 4: Figure S1A). Also, large proportions of patients
achieved LDA at month 12 with abatacept plus MTX
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Fig. 1 Overall remission rates at months 6 and 12 based on as-observed analyses for patients with data available at baseline, month 6 and month
12. Disease Activity Score 28 (DAS28) remission = DAS28 (C-reactive protein (CRP)) <2.6; Simplified Disease Activity Index (SDAI) remission = SDAI ≤3.3;
Clinical Disease Activity Index (CDAI) remission = ≤2.8. MTX methotrexate
Smolen et al. Arthritis Research & Therapy  (2015) 17:157 Page 4 of 12criteria – proportions were comparable regardless of the
index used, although numerically higher with the com-
bination (see Additional file 4: Figure S1B).
Remission rates at 6 months were lower but still consid-
erable (Fig. 1). Indeed, for patients receiving abatacept plus
MTX, remission rates increased by >50 % from months 6
to 12 with every index used; most patients reaching remis-
sion after 12 months were derived from those who had
already reached LDA at month 6. Indeed, for patients in
SDAI LDA at month 6, 68.5 % of patients receiving MTX
alone and 88.7 % receiving abatacept plus MTX maintained
LDA or achieved remission at month 12 (estimate of differ-
ence (95 % CI) 20.2 % (4.4, 36.0)). For patients in SDAI
MDA at month 6, 38.8 % of patients receiving MTX alone
and 50.8 % receiving abatacept plus MTX achieved LDA or
remission by month 12 (estimate of difference (95 % CI)
12.0 % (−5.6, 29.7); see Additional file 5: Figure S2).
Cumulative probability assessment
Cumulative probability plots to first SDAI LDA and remis-
sion and sustained first SDAI LDA and remission over
12 months are shown in Fig. 2 (Kaplan–Meier estima-
tion). Cumulative probability of achieving DAS28 and
CDAI remission and LDA within the first 6 months and
looking at 12-month outcomes are shown in Table 1. Pa-
tients receiving abatacept plus MTX were more likely to
achieve first remission or LDA than patients receiving
MTX alone, for all criteria. For LDA, all indices gave similar
probability of reaching LDA and time to achieve first or
sustained LDA. For remission, cumulative probabilities of
achieving SDAI or CDAI remission were lower than
DAS28, as expected. Although very stringent, regarding the
definition of sustained remission, these analyses highlightthat a higher proportion of patients receiving abatacept plus
MTX attained sustained LDA or remission than patients
receiving MTX alone. The median time to achieve first re-
mission was also longer for SDAI and CDAI than for
DAS28 (data not shown), indicating greater stringency.
Relationship between DAS28, SDAI and CDAI remission
Among patients receiving abatacept plus MTX who
achieved DAS28 remission, nearly all achieved at least
LDA according to SDAI or CDAI (Fig. 3); approximately
60 % and approximately 70 % also achieved SDAI or
CDAI remission at months 6 and 12, respectively, sug-
gesting some residual disease activity for patients in
DAS28 remission not achieving SDAI or CDAI remis-
sion. Few patients (1–4 %) in DAS28 remission were in
SDAI- or CDAI-defined MDA, with none in HDA. For
patients in SDAI or CDAI remission, nearly all patients
(91–100 %) also achieved DAS28 remission at both time
points in either treatment arm. With MTX alone, fewer
patients in DAS28 remission at month 12 achieved SDAI
or CDAI remission compared with those receiving aba-
tacept plus MTX. These data suggest that patients in
DAS28 remission receiving abatacept plus MTX may
have greater improvements in underlying disease com-
ponents than patients receiving MTX alone.
Core set variables
Median values for TJC, SJC, PGA, EGA, CRP and ESR
for patients achieving remission were numerically lower
for abatacept plus MTX versus MTX alone, irrespective
of the index employed (See Additional file 6: Figure S3).
The 3rd quartiles (or 75th percentile) of tender and
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Fig. 2 Cumulative probability plot for time to achieve first low disease activity (LDA)/remission or sustained LDA/remission. Cumulative probability plot to
achieve (a) first Simplified Disease Activity Index (SDAI) LDA, (b) first sustained SDAI LDA, (c) first SDAI remission, and (d) first sustained SDAI remission over
12 months (Kaplan–Meier estimation), based on patients with data available at baseline, month 6 and month 12. Cumulative probability and
corresponding 95 % CI were computed using Kaplan–Meier limit-product estimators. Patients who lost first LDA or remission status were censored at the
time of remission loss. SDAI LDA = SDAI ≤11; SDAI remission = SDAI ≤3.3; sustained remission was defined as maintained first LDA or remission at all
subsequent visits up to 12 months. Median time to achieve outcome corresponds to the time point when 50 % of patients achieved the outcome. Median
time was therefore not calculated if <50 % of patients achieved the outcome over the 12-month period. Median times (95 % CI) to first SDAI LDA and first
SDAI remission for the abatacept plus methotrexate (MTX) arm were 140.0 and 371.0 days, respectively. Median time (95 % CI) to first SDAI LDA for the
MTX arm was 197 days. Median time to achieve first SDAI remission cannot be defined in the MTX arm
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Table 1 Cumulative probability (95 % CI) of achieving first LDA/remission or sustained LDA/remission
First time
point at which 95 %
CI did not overlap, day
Cumulative probability (95 % CI) of achieving the specified state according to the
different indices
Month 6 Month 12
Abatacept + MTX MTX alone Abatacept + MTX MTX alone
First LDA DAS28 85 57.6 (50.9, 64.3) 43.5 (36.8, 50.3) 80.6 (75.2, 86.0) 67.6 (61.1, 74.0)
CDAI 85 60.5 (53.9, 67.1) 43.5 (36.8, 50.3) 83.3 (78.3, 88.4) 69.3 (63.0, 75.6)
First remission DAS28 57 40.0 (33.4, 46.6) 27.3 (21.3, 33.3) 70.2 (63.9, 76.4) 50.4 (43.5, 57.3)
CDAI 225 22.9 (17.2, 28.5) 14.4 (9.6, 19.1) 48.4 (41.6, 55.2) 31.2 (24.8, 37.5)
First sustained LDA DAS28 57 – – 54.8 (48.0, 61.5) 33.0 (26.6, 39.4)
CDAI 57 – – 58.6 (51.9, 65.2) 37.3 (30.8, 43.9)
First sustained remission DAS28 113 – – 38.6 (32.0, 45.2) 20.6 (15.1, 26.1)
CDAI 141 – – 24.8 (18.9, 30.6) 10.5 (6.4, 14.7)
Based on as-observed analyses for patients with data available at baseline, month 6 and month 12. Cumulative probability evaluated based on Kaplan–Meier estimation with
corresponding 95 % CI. First remission/LDA was defined by the first visit when the patient reached remission/LDA according to DAS28 and CDAI scores. Sustained remission/
LDA was defined as first remission or LDA status (according to DAS28 and CDAI scores) maintained at all subsequent visits up to month 12; patients who lost remission/LDA
status were censored at the time of remission/LDA loss. CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score 28, LDA low disease activity, MTX methotrexate
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maximum of 2 for SJC28 and 1 for TJC28), while the
median was 1 SJC28 and 0 TJC28 for patients in DAS28
remission (ranging up to a maximum of 6 SJC28 and 3
TJC28). In patients achieving remission status at month
12 but not at month 6, mean clinical core set variables
and mean SDAI, CDAI and DAS28 composite scores at

































































Fig. 3 Relationship between Disease Activity Score using 28-joint counts (DAS2
Activity Index (CDAI) status, based on patients with data available at baseline, m
(DAS28 remission = DAS28 <2.6); CDAI/SDAI disease activity states are mutually
defined as: SDAI remission = SDAI ≤3.3; SDAI low disease activity (LDA) = SDAI >
disease activity (HDA) = SDAI >26; CDAI remission = CDAI ≤3.3; CDAI LDA = CD
methotrexatenot yet in remission at month 6, patients experienced
major improvements in these variables.
Relationship between disease activity and function
Patients receiving abatacept plus MTX who achieved re-
mission or LDA according to DAS28, SDAI or CDAI at
month 3 achieved greater improvements in HAQ-DI























8) remission and Simplified Disease Activity Index (SDAI) and Clinical Disease
onth 6 and month 12 and achieving DAS28 remission at month 6 or 12
exclusive (a patient can be in only one category at any one time) and were
3.3–11; SDAI moderate disease activity (MDA) = SDAI >11–26; SDAI high
AI >2.8–10; CDAI MDA = CDAI >10–22; CDAI HDA = CDAI >22. MTX
Table 2 Clinical outcomes at month 6: patients in remission at month 12 but not month 6
Mean score
(SD) (95 % CI)
Patients in SDAI remission at month 12 but not month 6 Patients in CDAI remission at month 12 but not month 6
Abatacept + MTX (n = 36) MTX alone (n = 18) Abatacept + MTX (n = 37) MTX alone (n = 23)
Baseline Month 6 Baseline Month 6 Baseline Month 6 Baseline Month 6
DAS28 6.31 (1.01) 3.17 (1.03) (2.82, 3.52) 5.91 (1.10) 3.22 (1.16) (2.64, 3.79) 6.42 (0.97) 3.17 (1.02) (2.83, 3.51) 6.00 (1.07) 3.34 (1.11) (2.86, 3.82)
SDAI 48.73 (16.05) 11.57 (11.29) (7.75, 15.39) 43.71 (14.77) 11.89 (11.81) (6.02, 17.76) 49.67 (15.68) 11.31 (11.22) (7.57, 15.05) 44.58 (14.58) 12.20 (11.03) (7.42, 16.97)
CDAI 45.68 (14.86) 11.07 (11.18) (7.29, 14.85) 41.17 (14.69) 10.79 (11.34) (5.15, 16.43) 46.44 (14.57) 10.76 (11.12) (7.05, 14.47) 41.69 (13.91) 11.05 (10.65) (6.44, 15.65)
TJC28 17.28 (7.23) 4.17 (5.23) (2.40, 5.94) 15.11 (7.41) 4.06 (5.63) (1.26, 6.86) 17.43 (7.37) 3.97 (5.19) (2.24, 5.70) 15.52 (7.29) 4.26 (5.27) (1.98, 6.54)
SJC28 15.25 (6.15) 3.64 (5.16) (1.89, 5.38) 14.11 (5.71) 3.33 (4.98) (0.86, 5.81) 15.38 (6.09) 3.57 (5.10) (1.87, 5.27) 14.35 (5.42) 3.30 (4.68) (1.28, 5.33)
PGA (0–10 cm VAS) 6.57 (2.47) 2.20 (1.48) (1.70, 2.70) 5.66 (2.87) 1.77 (1.25) (1.14, 2.39) 6.92 (2.29) 2.24 (1.50) (1.74, 2.74) 5.67 (2.82) 1.88 (1.30) (1.32, 2.44)
EGA (0–10 cm VAS) 6.59 (2.02) 1.07 (1.09) (0.70, 1.43) 6.28 (2.12) 1.63 (1.22) (1.03, 2.24) 6.71 (1.87) 0.98 (1.07) (0.62, 1.33) 6.15 (1.95) 1.60 (1.15) (1.11, 2.10)
CRP (mg/dL) 3.05 (2.92) 0.50 (0.56) (0.31, 0.69) 2.54 (2.45) 1.10 (1.38) (0.42, 1.78) 3.24 (2.70) 0.56 (0.58) (0.36, 0.75) 2.89 (2.92) 1.15 (1.24) (0.61, 1.68)
ESR (mm/hour)* 47.93 (23.18) 22.60 (15.36) (14.09, 31.11) 39.11 (27.51) 19.22 (16.42) (6.60, 31.85) 49.06 (26.33) 24.94 (20.27) (14.14, 35.74) 46.18 (35.98) 26.36 (22.86) (11.00, 41.72)
*Numbers of patients: n = 15 for abatacept plus MTX and n = 9 for MTX alone for SDAI, and n = 16 for abatacept plus MTX and n = 11 for MTX alone for CDAI; as-observed data for patients with data at baseline,
month 6 and month 12. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joint counts, EGA evaluator’s global assessment, ESR erythrocyte sedimentation rate, MTX

















































































































































































































































































































































































































Fig. 4 Functional and structural outcomes at month 12 according to disease activity status. Functional (a–c) and structural (d–f) outcomes at month
12 according to disease activity status at months 3 and 12, based on patients with data available at baseline, month 6 and month 12.
*P <0.05; †Non-significant. Disease activity states are mutually exclusive (a patient can be in only one category at any one time) and were
defined as: Disease Activity Score using 28-joint counts (DAS28) remission = DAS28 <2.6; DAS28 low disease activity (LDA) = DAS28 2.6–3.2; DAS28
moderate disease activity (MDA)/high disease activity (HDA) = DAS28 >3.2; Simplified Disease Activity Index (SDAI) remission = SDAI ≤3.3;
SDAI LDA = SDAI >3.3–11; SDAI MDA/HDA = SDAI >11; Clinical Disease Activity Index (CDAI) remission = CDAI ≤3.3; CDAI LDA = CDAI >2.8–10; CDAI
MDA/HDA = CDAI >10. ANCOVA analysis of covariance, MTX methotrexate
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with greater improvements in HAQ-DI scores at month
12 for patients in remission or LDA at month 3 vs pa-
tients in MDA or HDA. Similar data were reported atdifferent time points. At all time points, in line with
their more stringent nature, mean HAQ-DI scores were
numerically lower for patients in SDAI and CDAI remis-
sion (with mean HAQ-DI score of ≤0.5 with MTX alone
Smolen et al. Arthritis Research & Therapy  (2015) 17:157 Page 9 of 12and ≤0.25 with abatacept plus MTX) versus DAS28 re-
mission (see Additional file 7: Table S4).
Relationship between disease activity and structural
outcomes
Structural damage progression assessed by change in
TGSS at month 12 was evaluated according to disease
activity status at months 3 and 12 (Fig. 4d–f ). Patients
who achieved remission at months 3 or 12 had only
minimal change from baseline in TGSS over 12 months
of abatacept plus MTX or MTX alone. However, for pa-
tients continuing to be in MDA/HDA at 3 months, esti-
mates of treatment difference and associated exploratory
P values demonstrated that less structural damage pro-
gression was seen in those treated with abatacept plus
MTX than in those treated with MTX alone, although
progression was not abrogated completely (adjusted
mean treatment group differences (95 % CI) were: −0.61
(−1.11, −0.11), P <0.05, for patients in DAS28 MDA/
HDA at month 3; −0.60 (−1.11, −0.09), P <0.05, for pa-
tients in SDAI MDA/HDA at month 3; and −0.62
(−1.13, −0.11), P <0.05, for patients in CDAI MDA/HDA
at month 3; Fig. 4d–f, left panels).
Change from baseline in TGSS at month 12 was also
evaluated according to patients’ disease activity status at
month 12 (Fig. 4d–f, right panels). Patients treated with
abatacept plus MTX who were in MDA/HDA at month
12 had numerically greater changes from baseline com-
pared with patients in LDA or remission. Estimates of
treatment difference and associated exploratory P values
also showed that patients treated with abatacept plus
MTX in MDA/HDA tended to have numerically better
outcomes in terms of structural damage progression
than those treated with MTX alone (adjusted mean
treatment group differences (95 % CI) were: −0.68
(−1.33, −0.03), P < 0.05, for patients in DAS28 MDA/
HDA at month 12; −0.50 (−1.18, 0.18), P = 0.146, for pa-
tients in SDAI MDA/HDA at month 12; and −0.51
(−1.18, 0.17), P = 0.139, for patients in CDAI MDA/
HDA at month 12).
Discussion
In the AGREE study, MTX-naïve patients with early RA
who had been treated with abatacept plus MTX experi-
enced clinical, functional and structural benefits, and
improvements in disease activity, versus patients treated
with MTX alone [15]. In these post hoc analyses, high
proportions of patients receiving abatacept plus MTX
achieved remission at months 6 and 12 according to the
stringent ACR-EULAR index-based SDAI (19 and 33 %,
respectively) and CDAI (19 and 34 %, respectively) cri-
teria. Higher proportions of patients achieved remission
according to DAS28 (31 and 48 % at months 6 and 12)
compared with SDAI, CDAI and Boolean criteria. Thiswas not surprising as it is well established that DAS28
remission criteria frequently are afflicted with significant
residual disease activity, both clinically and by sonog-
raphy [4–9]. Interestingly, the difference between DAS28
remission rates and SDAI/CDAI remission rates was
generally smaller here [21–24], presumably because aba-
tacept, unlike some other biologic agents [21], may not
directly influence the acute-phase response, which is
heavily weighted in the DAS28 formula. However, the
DAS28 remission rates observed at 6 months were simi-
lar to those previously observed with other biologic
agents. Rates for patients achieving Boolean-defined re-
mission (with laboratory measures) were also relatively
high for patients treated with abatacept plus MTX (15
and 24 % at months 6 and 12). These findings demon-
strate that remission according to the stringent ACR-
EULAR remission criteria (SDAI, CDAI and Boolean) is
indeed frequently achievable in clinical trials in many
MTX-naïve patients treated with MTX, and in even
greater proportions of patients receiving biologic therapy
(in this case abatacept) in combination with MTX. These
results were not dissimilar to those observed in clinical
practice, where SDAI and CDAI remission outcomes
have been seen in approximately 20–25 % of patients
[25].
Analyses of disease activity based on different indices
have been performed for other populations of patients
treated with abatacept, including those with established
RA refractory to MTX [26, 27], and similar to other bio-
logic agents, remission rates are lower for patients with
refractory disease treated with abatacept plus MTX/
DMARDs than for those in the MTX-naïve population,
especially for achieving the stringent SDAI-derived cri-
teria [28, 29].
Cumulative probability plots have shown that patients
receiving abatacept plus MTX reached stringent first
remission targets at earlier time points than patients re-
ceiving MTX alone; this may have an impact on func-
tional and structural outcomes, and so is important to
evaluate [2].
As anticipated, not all patients in DAS28 remission
also achieved SDAI or CDAI remission, although a large
proportion of patients were in SDAI or CDAI LDA,
highlighting that it is more difficult to achieve remission
according to these stringent criteria or that - in line with
the data shown here - DAS28 "remission" comprises
many patients with significant residual disease activity
which are rightly captured as not being in remission by
ACR-EULAR remission criteria and as being in an active
disease state by SDAI and CDAI.
For abatacept plus MTX, the proportions of patients
achieving stringent remission increased from month 6 to
month 12 regardless of the index used, highlighting an
increasing magnitude of response over time, even in this
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servations, which have not been reported previously with
other biologic agents, suggest that the efficacy of abata-
cept plus MTX may not peak at 6 months, but appears
to continue to increase after month 6, allowing more pa-
tients to reach the therapeutic goals of SDAI and CDAI
remission with continued therapy. These findings are sup-
ported by the recently updated EULAR recommendations
for the management of RA with DMARDs, which state
that individual patients may take longer than 6 months to
achieve remission, and that in such cases change in disease
activity from baseline should also be taken into consider-
ation [30]. Moreover, these findings highlight the value of
the LDA target in the treat-to-target recommendations
[31–35] and also support the ACR-EULAR recommenda-
tions to report not only achievement but also maintenance
of outcomes and sustainability of remission [2].
Finally, we evaluated the association between remission
of clinical disease activity at early time points (month 3)
with functional and structural outcomes over the 12-month
period. Patients who achieved clinical remission demon-
strated numerically greater improvements in physical func-
tion, especially versus patients in MDA/HDA, regardless of
the index used, supporting an association between early
suppression of inflammation and long-term functional
benefit. The best functional outcomes were achieved with
SDAI and CDAI remission. Mean changes in radiographic
score were numerically lower for patients in remission
or LDA versus MDA/HDA; this difference was less pro-
nounced for patients receiving abatacept plus MTX.
Importantly, adjusted mean differences and exploratory
P values (i.e., not based on prespecified analyses) show
a difference between patients in MDA/HDA treated
with abatacept plus MTX versus MTX alone, suggest-
ing a dissociation of the profound relationship between
inflammation and destruction, as seen previously for
tumor necrosis factor inhibitors, tocilizumab and rituximab
[31–35]. Altogether, these findings further highlight the
value of targeting stringent remission outcomes, as recom-
mended by ACR-EULAR [2].
The limitations of this post hoc descriptive analysis
should be taken into consideration when interpreting these
data. The population analyzed here represents a subset of
the original AGREE study, including only patients with
complete datasets. The analyses were neither prespecified
nor powered to detect between- or within-group differ-
ences. However, only 90/509 randomized patients were ex-
cluded from the analysis, which provides a relatively large
sample size, and even if those patients excluded had been
included and none had achieved remission, the overall pro-
portion of patients achieving remission would likely have
still been substantial, especially for patients treated with
abatacept plus MTX. Nevertheless, the findings presented
here would benefit from validation in a larger population.Conclusions
In summary, in contrast to commonly held beliefs [13, 14],
relatively high proportions of patients can achieve at least
low disease activity or remission by the ACR-EULAR cri-
teria, despite, and at the same time because of, their strin-
gency; this was seen for MTX and was more pronounced
for treatment with abatacept plus MTX. In the AGREE
study, many patients attained low disease activity, an alter-
native therapeutic target to remission. Furthermore, the
regular assessment of remission in this study may have re-
sulted in patients with transient fluctuations in disease ac-
tivity failing to achieve the study definition of sustained
remission (i.e., maintenance of first remission at all subse-
quent monthly visits up to month 12), and may have led to
an underestimation of sustained remission. Some data sug-
gest that higher rates of remission can be observed in ob-
servational datasets and clinical trials when a treat-to-target
strategy is adopted [25, 36]. More recent trials of abatacept
in MTX-naïve patients with early progressive RA have re-
ported higher rates of remission than reported here, even
when using stringent remission criteria [37]. This trend is
thought to reflect the increasing use of biologic DMARDs
earlier in the course of RA disease, patients entering clinical
trials having shorter disease duration and lower disease ac-
tivity at baseline. Nevertheless, these present analyses sup-
port the use of viable treatment targets in the therapy of
patients with RA.Additional files
Additional file 1: Core components comprising disease activity
indices. This table shows the core components and overall cutoff values
used to define Disease Activity Score 28 (DAS28), Simplified Disease
Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and Boolean
remission.
Additional file 2: Baseline demographics and clinical characteristics.
This table contains the baseline demographics and clinical characteristics
for patients with data available at baseline, month 6 and month 12.
Additional file 3: Baseline demographics and clinical characteristics
according to Simplified Disease Activity Index (SDAI) and Disease
Activity Score 28 (DAS28) disease activity at month 12. This table
contains the baseline demographics and clinical characteristics for
patients with data available at baseline, month 6 and month 12,
according to their SDAI and DAS28 disease activity (low, moderate, high,
remission) at month 12.
Additional file 4: Additional disease activity outcomes. This file
contains a multi-part figure. A Boolean remission rates at month 6 and
month 12 in the abatacept plus methotrexate (MTX) and MTX alone treatment
groups, comparing three definitions of Boolean remission (three criteria
(28 joints), all criteria (66/68 joints), three criteria (66/68 joints)). B Rates
of low disease activity (LDA) at months 6 and 12, comparing three criteria for
assessing LDA (Disease Activity Score 28 (DAS28), Simplified Disease Activity
Index (SDAI) and Clinical Disease Activity Index (CDAI)).
Additional file 5: Shifts in Simplified Disease Activity Index (SDAI)
category from month 6 to month 12. This figure shows the change in
SDAI disease activity (low (LDA), moderate (MDA), high (HDA), or
remission) between month 6 and month 12 in the abatacept plus
methotrexate (MTX) and MTX alone treatment groups.
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table contains a multi-part figure comparing core set variables at month
6 in patients who achieve Disease Activity Score 28 (DAS28), Clinical Disease
Activity Index (CDAI) or Simplified Disease Activity Index (SDAI) remission.
Figure A shows patient and physician assessment of global disease activity,
Figure B shows swollen and tender joint counts, and Figure C shows
C-reactive protein level and erythrocyte sedimentation rate.
Additional file 7: Functional outcomes according to the Simplified
Disease Activity Index (SDAI). This table shows the mean (standard
deviation) physical function, as assessed by Health Assessment
Questionnaire-Disability Index (HAQ-DI) score, according to SDAI disease
activity state (low, moderate/high, remission) at months 3, 6 and 12.
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